Idiopathic Pulmonary Fibrosis

Treatment of IPF

Treatment of IPF

Anti-fibrotic medications are available through interstitial lung disease (ILD) Specialist Centres in England and through general hospitals in Scotland, Wales and Northern Ireland.

Although not curative, anti-fibrotics such as OFEV® (nintedanib) are proven to slow the rate of forced vital capacity (FVC) decline for patients with IPF, so it is essential that eligible patients have access to them as soon as possible.1-3

Quick links

Quick links

Management of IPF

Once referred to an ILD Specialist Centre, patients have access to a range of interventions and support materials, which has been shown to improve their outcomes.4

IPF management may include medical treatment, pulmonary rehabilitation to help manage symptoms, supplemental oxygen to keep oxygen levels at a healthy level or lung transplantation.

Commitment to progress

Thanks to the commitment of the ILD community and Boehringer Ingelheim, significant progress has been made for these rare diseases over the past decade. Awareness, knowledge and understanding of the role fibrosis plays in disease progression has grown. Since the introduction of anti-fibrotic treatments for IPF, such as OFEV® (nintedanib) which can now also be used to treat chronic progressive fibrotic ILD, care pathways and referral processes have steadily improved, providing much-needed opportunities for patients to access the vital care and treatment they need to slow disease progression and gain more time free from serious and debilitating events.2,5

References

References

1.

OFEV® 100 mg and 150 mg soft capsules Summary of Product Characteristics. Boehringer Ingelheim.

2.

Richeldi L et al. N Engl J Med. 2014;370(22):2071–2082.

3.

Cottin V, Richeldi L. Eur Respir Rev. 2014;23(131):106–110.

4.

Molina-Molina M et al. Exp Rev Resp Med. 2018;12(7):537–539.

5.

Flaherty KR et al. N Engl J Med 2019;381(18):1718–1727.

Related products

Find out more information about OFEV® (nintedanib) below

OFEV® (nintedanib) is indicated in adults for the treatment of idiopathic pulmonary fibrosis (IPF) and for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.

PC-GB-106292

March 2022

Reporting adverse events

Adverse events should be reported. Reporting form and information can be found atwww.mhra.gov.uk/yellowcard. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on0800 328 1627 (freephone).

Please be aware that this website contains promotional information about Boehringer Ingelheim medicines and services. Some of this may not be directly relevant to your scope of practice and it is your own decision whether you choose to view this information.